Trial Profile
Pilot Study of Ixazomib to Reduce the Number of HIV DNA Positive Lymphoid Cells
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 08 Jan 2022 Status changed from active, no longer recruiting to completed.
- 08 Feb 2021 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.
- 21 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Jan 2021.